CHINARESPHARMA：InterimReport2020.pdf

《CHINARESPHARMA：InterimReport2020.pdf》由会员分享，可在线阅读，更多相关《CHINARESPHARMA：InterimReport2020.pdf（87页珍藏版）》请在三个皮匠报告上搜索。

1、(Stock Code 股份代號:3320)Interim Report 2020中期報告02公司簡介Corporate Profile03公司資料Corporate Information06釋義Definitions09管理層討論及分析Management Discussion and Analysis32其他資料Other Information37簡明綜合財務報表審閱報告Report on Review of Condensed Consolidated Financial Statements39中期簡明綜合損益表Interim Condensed Consolidated Stat

2、ement of Profit or Loss40中期簡明綜合全面收益表Interim Condensed Consolidated Statement of Comprehensive Income41中期簡明綜合財務狀況報表Interim Condensed Consolidated Statement of Financial Position43中期簡明綜合權益變動表Interim Condensed Consolidated Statement of Changes in Equity45中期簡明綜合現金流量表Interim Condensed Consolidated Statem

3、ent of Cash Flows49中期簡明綜合財務報表附註Notes to Interim Condensed Consolidated Financial StatementsThis interim report is printed on environmentally friendly paper此中期報告以環保紙張印製目錄Contents02公司簡介Corporate Profile China Resources Pharmaceutical Group Limited Interim Report 2020China Resources Pharmaceutical Grou

4、p Limited(stock code:3320)is a leading integrated pharmaceutical company in China.Our business spans across manufacturing,distribution and retail of pharmaceutical and healthcare products.Since the establishment in 2007,the Group has developed into one of the fifth largest pharmaceutical manufacture

5、rs and the one of the third largest pharmaceutical distributors(by revenue)in China.In October 2016,the Company successfully completed its global offering in Hong Kong.Since its listing,the Company has been included in a number of capital market indexes such as MSCI China Index,FTSE Global Large Cap

6、 Index,constituent stock of Hang Seng Composite Large Cap Index and Hang Seng Corporate Sustainability Index,reflecting a global recognition by the international capital markets on the Groups business performance,growth potential,market capitalization,and share liquidity.Our manufacturing business e